Eledon Pharmaceuticals, Inc.ELDNNASDAQ
LOADING
|||
ELDN Revenue Growth (YoY Quarterly)•+0.00%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -122.68% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -121.55% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +73.30% | +146.93% | +157.18% | +82.50% | +48.53% |
| Weighted Average Shares Diluted Growth | +85.09% | +146.93% | +157.18% | +82.50% | +39.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +19.26% | +99.18% | +99.59% | +20.27% | +13.34% |
| Book Value per Share Growth | -51.95% | +563.76% | +0.00% | +0.00% | -68.70% |
| Debt Growth | +4.59% | +149.09% | +209.86% | +22.60% | +44.11% |
| R&D Expense Growth | +108.30% | +153.69% | +82.60% | +100.63% | -9.39% |
| SG&A Expenses Growth | +28.90% | +110.26% | +31.78% | +3.68% | +0.27% |
1 / 4